113 results about "Muscle actin" patented technology

The invention discloses application of lupane derivatives in preparation of medicines for preventing and / or treating drug-induced deafness, and belongs to the field of biological medicines. The lupane derivative is represented by Chiisanoside, and experiments prove that the lupane derivative can activate the expression of Dock1 and PIP5K1A, inhibit the expression of Gelsolin and inhibit hair cytoskeleton actin instability induced by ototoxic drugs, and the lupane derivative has the advantages that the lupane derivative can be used for inhibiting the ototoxic drug-induced hair cytoskeleton actin instability, and the lupane derivative can be used for inhibiting the ototoxic drug-induced hair cytoskeleton actin instability; in addition, by activating expression of TGFBR2, SLC7A11 and GPX4 at the same time, hair cell ferroptosis induced by ototoxic drugs can be inhibited; further, the effects of preventing, treating or relieving the drug-induced deafness are exerted. The lupane derivative disclosed by the invention can be further developed into a multi-target therapeutic drug for preventing, treating and relieving drug-induced deafness.

A wearable heart monitoring device includes a carrier and a housing. The carrier includes a first electrode defining a sensor configured to measure at least one of b-type natriuretic peptide (BNP), N-terminal pro b-type natriuretic peptide (NT-proBNP), or Troponin. Moreover, a second electrode is configured to measure at least one of parameter associated with a heart, heart disease, or heart disease treatment, of a patient wearing the heart monitoring device. The housing includes an adhesive thereon. The housing is coupled to the carrier. Moreover, the housing contains a controller communicably coupled to the first electrode and the second electrode, memory coupled to the controller, and a communication interface communicably coupled to the controller.

Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI / SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and / or SMARCA4).

Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI / SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and / or SMARCA4). I

Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI / SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and / or SMARCA4).

Disclosed are compounds that are useful for modulating or degrading protein which is expressed from one or more SWI / SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and / or SMARCA4).

The invention belongs to the technical field of medicines, and particularly discloses application of binding molecules of actin binding protein LASP1 in prevention and treatment of acute respiratory distress syndrome (ARDS). According to the invention, the LASP1-loaded nanoparticles are constructed, so that the problems that the drug is difficult to penetrate and easy to remove and degrade and the ARDS is difficult to treat are solved. According to the invention, through intranasal instillation of the HA-DA / BP / LASP1 nanoparticles, the level of inflammatory factors can be reduced, the alveolar epithelial barrier structure and function can be repaired, and the death rate of ARDS model mice can be reduced.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

To provide actin reorganization inhibitors and phagocytosis inhibitors, which inhibit the actin reorganization and induction of phagocytosis in epidermal keratinocytes by contacting the epidermal keratinocytes with a fibroblast conditioned medium; to provide stain formation inhibitors containing the inhibitor; and to provide external skin preparations containing the inhibitor.SOLUTION: Provided is an inhibitor that inhibits the actin reorganization and induction of phagocytosis in epidermal keratinocytes by contacting the epidermal keratinocytes with a fibroblast conditioned medium, and contains a specific plant extract or a specific compound as an active ingredient. Also provided are a spot formation inhibitor composed of the inhibitor, and a skin external preparation containing the inhibitor.SELECTED DRAWING: None

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI / SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and / or polybromo-1 (PB-1) protein via ubiquitination and / or degradation by compounds. The compounds are bifunctional molecules that link a cereblon-binding moiety to a ligand that binds SMARCA and / or PB1 proteins.

The invention relates to a preparation method and application of novel rhizoma bletillae glucomannan. The preparation method of the rhizoma bletillae glucomannan comprises the following steps: 1, drying, crushing and sieving rhizomes of a raw material rhizoma bletillae; 2, putting the crushed and sieved rhizoma bletillae into ethanol for degreasing; 3, obtaining crude polysaccharide through a distilled water ice bath ultrasonic extraction technology and an ethanol precipitation technology; 4, separating and purifying through a DEAE-52 cellulose column and a G-150 gel column to obtain the high-purity rhizoma bletillae homogeneous polysaccharide BsPsIII1-1, namely the rhizoma bletillae glucomannan; 5, carrying out semipermeable membrane dialysis on the BsPsIII1-1 to remove salt, and carrying out freeze drying; and 6, carrying out chemical analysis on the obtained BsPsIII1-1. According to the preparation method and the application of the novel rhizoma bletillae glucomannan, animal experiments show that BsPsIII1-1 can significantly improve CCl4 induced mouse liver tissue injury, reduce serum ALT and AST levels, effectively relieve oxidative stress by reducing MDA content and increasing GSH level, and significantly inhibit hepatic fibrosis by down-regulating expression of alpha smooth muscle actin (alpha-SMA) and collagen I (COL-1).

The invention discloses an application of senkyunolide I in preparation of a medicine for treating hepatic fibrosis, which can obviously inhibit HSC (hepatic stellate cell) activation in vitro and evaluate the treatment effect of senkyunolide I on hepatic fibrosis in vivo by adopting a C57BL / 6 mouse hepatic fibrosis model induced by CCl4. The expression levels of liver alpha-smooth muscle actin, type I collagen and matrix metalloproteinase tissue inhibition factor 1 of individuals needing anti-hepatic fibrosis are obviously reduced in vivo and in vitro, and the hepatic fibrosis progress can be effectively intervened. Therefore, according to the application of the senkyunolide I in the hepatic fibrosis, the provided compound senkyunolide I has huge potential for inhibiting the hepatic fibrosis, an effective traditional Chinese medicine monomer component medicine is provided for treating the hepatic fibrosis, the new clinical adaptation application of the senkyunolide I is expanded, and the application prospect is good.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

The present application relates to the technical field of health care products, in particular to a pelvic floor muscle repairing composition containing supermolecular tightening Dropsordry and a preparation method thereof, which comprises the following components in mass fraction: 10-14 parts of protein composition, 20-24 parts of chitosan modified Dropsordry, 5-7 parts of freeze-dried powder of Lactobacillus bulgaricus, 10-12 parts of hyaluronic acid, 6-8 parts of glycine and 15-17 parts of proline; each part of the protein composition comprises 20-30 parts of myosin, 30-34 parts of actin, 5-10 parts of hydrolyzed collagen and 240-280 parts of deionized water. The pelvic floor muscle repairing composition can reduce drug toxicity, reduce the amount of drug administration, continuously supplement the required elements of the body during treatment, and quickly relieve the constipation problem caused by the functional damage of the pelvic floor muscle.

The present invention relates to a novel compound which modulates the function and differentiation of a cytoskeleton involved in pulmonary fibrosis and thus can be used for preparing a medicament capable of treating related diseases. It has been determined that: the novel compound according to the present invention or a pharmaceutically acceptable salt thereof has an effect of modulating actin polymerization required for cytoskeleton formation; and the expression of alpha-SMA and F-actin, which are main factors causing fibrosis, is effectively inhibited in human lung tissue-derived fibroblasts (MRC5). Furthermore, it has been determined that when activated macrophages are treated with the compounds, the level of inflammation of inflammatory cytokines caused by the macrophages is reduced. Therefore, the novel compound according to the present invention is expected to be effectively used in the prevention and treatment of diseases associated with pulmonary fibrosis as a preparation having an effect of inhibiting or reducing pulmonary fibrosis.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

Radiolabelled binding agents that specifically bind to F-actin are provided. In particular, the radiolabelled binding agents of the invention exhibit preferential binding for F-actin over G-actin, which enables them to be used in medical and research settings. The invention provides radiolabelled binding agents, medical uses thereof, methods of generating radiolabelled binding agents and kits.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The gene editing technology was used to carry out target knockout of zc3h12b gene of Oryzias latipes, establishing Oryzias latipes missing Zc3h12b protein product. The established Oryzias latipes all show different degrees of liver lesions such as hepatobiliary duct hyperplasia and fusion, hepatocyte steatosis, and fibrosis. With increase of months, significant fatty liver appears with local cyst necrosis, obvious lymphocyte infiltration in liver sinusoids and abnormal increase in number of macrophages. Human tumor markers cytokeratin 19 (CK19), smooth muscle actin (SMA) and glypican-3 (GPC3) positive cells are also detected. It is suggested that ZC3H12B can be used as a treatment target and a biomarker for biliary cystadenoma (BCA), biliary cystadenocarcinoma (BCAC), or fatty liver or liver cancer related to BCA or BCAC. The zc3h12b missing Oryzias latipes can be used as an animal model in researches on pathological processes of BCA, BCAC, or fatty liver or liver cancer related to BCA or BCAC.

Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI / SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and / or SMARCA4).

Disclosed herein are adapted dystrophin proteins (e.g., adapted mini- or micro-dystrophin proteins), nucleic acid molecules and vectors encoding the same, as well as methods of treating a muscular dystrophy (e.g., Duchenne or Becker muscular dystrophy), for example by gene therapy comprising the adapted dystrophin proteins, the nucleic acid molecules, or the vectors of the disclosure.

The invention discloses rhizoma acori graminei polysaccharide as well as a preparation method and application thereof. According to the method disclosed by the invention, the acorus tatarinowii polysaccharide is obtained from the root tuber of the acorus tatarinowii Schott by adopting the methods of water extraction, alcohol precipitation and column separation and purification. Cell experiment results show that the rhizoma acori graminei polysaccharide can significantly inhibit activation of TGF-beta induced hepatic stellate cells (LX-2), and carbon tetrachloride (CCl4) induced hepatic fibrosis mouse model experiments show that the rhizoma acori graminei polysaccharide can significantly reduce CCl4 induced collagen deposition and expression of liver tissue alpha-smooth muscle actin (alpha-SMA), and can significantly inhibit TGF-beta induced hepatic stellate cells (LX-2) activation. The content of asparaginic acid aminotransferase (AST), alanine aminotransferase (ALT) and the like in serum of a hepatic fibrosis model mouse is reduced, and the compound can be used for preparing candidate carbohydrate drugs or liver protection health care products for treating and / or treating hepatic fibrosis.

The invention discloses application of arabinoxylan (AX) in preparation of a medicine for treating chronic obstructive pulmonary disease (COPD), and belongs to the technical field of medicines. The arabinoxylan (AX) can be used for preparing a medicine for treating the COPD (chronic obstructive pulmonary disease). Through a large number of researches, the inventor of the application finds that AX has a remarkable COPD treatment effect: lung inflammation in a mouse COPD model caused by haze can be reduced, the expression is that infiltration of mature T lymphocytes and macrophages in lung tissues is reduced, and the expression level of various proinflammatory factors including TGF-beta1 is reduced; the compound can weaken extracellular matrix deposition in the lung of a COPD mouse caused by haze, reduce the thickness of a tracheal wall, and reduce the expression of I-type collagen (collagen I) and a myofibroblast marker smooth muscle alpha2-actin (alpha-Sma); the emphysema degree of a COPD mouse induced by haze is also relieved; the AX also relieves abnormal changes of related protein levels of iron metabolism, mitochondrial metabolism, oxidative stress and glycometabolism in the lung tissue of the COPD mouse induced by haze. Therefore, AX can be used for preparing the medicine for treating COPD.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

The invention relates to sesquiterpenoids Oxyphyllene F and Oxyphyllene G which are separated from fructus alpiniae oxyphyllae and application of the sesquiterpenoids Oxyphyllene G. Experimental research finds that the two compounds can inhibit the expression of fibronectin, type I collagen and alpha-smooth muscle actin in rat renal tubular duct epithelial cells induced by TGF-beta1, have anti-renal fibrosis activity, and can be used for preparing anti-renal fibrosis drugs. The fructus alpiniae oxyphyllae can be effectively used for preparing kidney protection drugs, the preparation method is good in reproducibility, the purity of the obtained compound is high, further pharmacological and clinical research on the compound is facilitated, the medicinal value of the fructus alpiniae oxyphyllae is expanded, and the economic and social benefits are huge.

The invention provides a biomarker combination for evaluating the progress of abdominal aortic aneurysm based on an adventitia and application of the biomarker combination, and the biomarker combination comprises at least two biomarkers selected from the following three independent groups, the at least two markers are from the same group or different groups: a myofibroblast transformation marker group: alpha-smooth muscle actin, monocyte chemotactic protein 1 and a tissue metalloproteinase inhibitor 1; the lipid metabolism related biomarker group comprises a lipid metabolism related protein CD36, carnitine palmitoyl transferase 1 and a fatty acid binding protein 4; and an inflammatory factor related biomarker group: IL-6, MCP-1 and TIMP1. According to the biological marker combination for evaluating the progress of the abdominal aortic aneurysm based on the adventitia, multi-channel biological markers are systematically integrated, an innovative tool is provided for accurate diagnosis, drug screening and curative effect monitoring of AAA, and meanwhile, an important foundation is laid for developing a collaborative treatment strategy based on adventitia fibroblast regulation.

The invention belongs to the technical field of biological medicines, and discloses a deep sea steroid compound, a preparation method thereof and application of the deep sea steroid compound in preparation of medicines for preventing or treating renal fibrosis. The steroid compound is a class of highly oxidized and modified ergoketone compounds, and in some embodiments, the compound has an unusual malonyl substitution at the C-12 position of an ergoketone skeleton. The steroidal compound disclosed by the invention can achieve the effect of inhibiting renal fibrosis by regulating and controlling expression down-regulation of key fibrosis markers, namely alpha-smooth muscle actin (alpha-SMA) and I-type collagen (COL1A1), and has an inhibiting effect on proliferation of TGF-beta1-induced mouse renal fibroblasts; therefore, the compound has a great application prospect in preparation of drugs for preventing or treating renal fibrosis.